Browsing Tag
BCell
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial…
<!-- Name:DistributionId Value:8744827 -->
<!--…
Read More...
Read More...
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a…
Goal is to report initial SC291 clinical data this year Goal is to submit a second IND from the platform this year for…
Read More...
Read More...
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate…
The first patient completed the 28-day Dose Limiting Toxicity (DLT) observation period without complication NEW YORK,…
Read More...
Read More...
Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic…
Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein…
Read More...
Read More...
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate…
UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’…
Read More...
Read More...
Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma
Treatment with second-line…
Read More...
Read More...
Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma,…
Irreversible covalent menin inhibitor, BMF-219, exhibited high potency and complete growth inhibition in high-grade…
Read More...
Read More...
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated…
— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760…
Read More...
Read More...